Nemucore Medical Innovations Overview
- Year Founded
-
2008
- Status
-
Out of Business
- Employees
-
6
- Latest Deal Type
-
Out of Business
Nemucore Medical Innovations General Information
Description
Operator of a drug development company intended to offer molecularly targeted nanomedicines. The company's clinical development services include the development and commercialization of NMI-900, a life-saving, molecularly targeted therapeutic, which is an aurora B Kinase inhibitor that evades cancer defenses and delivers medications that can treat tumors, enabling cancer patients to treat newly diagnosed, recurrent, and multidrug-resistant cancers.
Contact Information
Website
www.nemucore.comCorporate Office
- One Hollis Street
- Suite 232
- Wellesley, MA 02482
- United States
Corporate Office
- One Hollis Street
- Suite 232
- Wellesley, MA 02482
- United States
Nemucore Medical Innovations Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Out of Business | 05-Oct-2026 | Completed | Out of Business | |||
| 9. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 8. Equity Crowdfunding | 30-Apr-2018 | Completed | Generating Revenue | |||
| 7. Grant | 31-Jan-2016 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series A) | 07-Dec-2015 | Completed | Generating Revenue | |||
| 5. Grant | 31-Jul-2015 | Completed | Generating Revenue | |||
| 4. Grant | 01-Jan-2013 | Completed | Generating Revenue | |||
| 3. Grant | 31-Aug-2012 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 10-Apr-2012 | Completed | Generating Revenue | |||
| 1. Grant | 01-Jan-2010 | $302K | Completed | Generating Revenue |
Nemucore Medical Innovations Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Nemucore Medical Innovations Patents
Nemucore Medical Innovations Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3138517-A1 | Degradation of aurora kinase (aurk) by conjugation of aurk inhibitors with e3 ligase ligand | Pending | 01-May-2019 | ||
| EP-3962480-A1 | Degradation of aurora kinase (aurk) by conjugation of aurk inhibitors with e3 ligase ligand | Inactive | 01-May-2019 | ||
| EP-3962480-A4 | Degradation of aurora kinase (aurk) by conjugation of aurk inhibitors with e3 ligase ligand | Inactive | 01-May-2019 | ||
| US-20220218831-A1 | Degradation of aurora kinase (aurk) by conjugation of aurk inhibitors with e3 ligase ligand | Inactive | 01-May-2019 | ||
| WO-2020223456-A1 | Degradation of aurora kinase (aurk) by conjugation of aurk inhibitors with e3 ligase ligand | Inactive | 01-May-2019 | A61K47/556 |
Nemucore Medical Innovations Signals
Nemucore Medical Innovations FAQs
-
When was Nemucore Medical Innovations founded?
Nemucore Medical Innovations was founded in 2008.
-
Where is Nemucore Medical Innovations headquartered?
Nemucore Medical Innovations is headquartered in Wellesley, MA.
-
What is the size of Nemucore Medical Innovations?
Nemucore Medical Innovations has 6 total employees.
-
What industry is Nemucore Medical Innovations in?
Nemucore Medical Innovations’s primary industry is Drug Discovery.
-
Is Nemucore Medical Innovations a private or public company?
Nemucore Medical Innovations is a Private company.
-
What is Nemucore Medical Innovations’s current revenue?
The current revenue for Nemucore Medical Innovations is .
-
How much funding has Nemucore Medical Innovations raised over time?
Nemucore Medical Innovations has raised $1.09M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process